{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MDS&page=30",
    "query": {
      "condition": "MDS",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 1861,
    "total_pages": 187,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MDS&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MDS&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T19:26:50.872Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07468916",
      "title": "Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atypical Chronic Myeloid Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified",
        "Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Ropeginterferon Alfa-2B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2026-09-29",
      "completion_date": "2032-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07468916"
    },
    {
      "nct_id": "NCT01311258",
      "title": "Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2007-08",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01311258"
    },
    {
      "nct_id": "NCT03630991",
      "title": "Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "High Risk Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Myeloproliferative Neoplasm",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Recurrent Myelodysplastic Syndrome",
        "Recurrent Myelodysplastic/Myeloproliferative Neoplasm",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Refractory Myelodysplastic Syndrome",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndrome",
        "Very High Risk Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Edetate Calcium Disodium",
          "type": "DRUG"
        },
        {
          "name": "Multivitamin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Succimer",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 58,
      "start_date": "2018-10-11",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630991"
    },
    {
      "nct_id": "NCT00589316",
      "title": "Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Myeloid Leukemia in Remission",
        "CD45-Positive Neoplastic Cells Present",
        "Chronic Myelomonocytic Leukemia",
        "Previously Treated Myelodysplastic Syndrome",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Ring Sideroblasts",
        "Refractory Cytopenia With Multilineage Dysplasia",
        "Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts"
      ],
      "interventions": [
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Iodine I 131 Monoclonal Antibody BC8",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2007-10-05",
      "completion_date": "2021-10-01",
      "has_results": true,
      "last_update_posted_date": "2023-02-09",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589316"
    },
    {
      "nct_id": "NCT06960993",
      "title": "Mosaic Trial for Stem Cell Transplant Recipients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hematologic Malignancy",
        "Stem Cell Transplant",
        "Bone Marrow Transplant",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Intervention website",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhanced Usual Care (Control) Website",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 356,
      "start_date": "2025-04-28",
      "completion_date": "2030-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Nutley, New Jersey",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Nutley",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06960993"
    },
    {
      "nct_id": "NCT03755414",
      "title": "Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphocytic Leukemia",
        "Myelodysplastic Syndromes",
        "Non-Hodgkin Lymphoma",
        "Hodgkin Disease"
      ],
      "interventions": [
        {
          "name": "Stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)",
          "type": "OTHER"
        },
        {
          "name": "Human Activity Profile",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2019-09-04",
      "completion_date": "2024-05-26",
      "has_results": true,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03755414"
    },
    {
      "nct_id": "NCT05998408",
      "title": "JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Aplastic Anemia",
        "Single Lineage Cytopenias, T-LGL",
        "Hypoplastic MDS"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 13,
      "start_date": "2024-02-20",
      "completion_date": "2032-06-03",
      "has_results": true,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05998408"
    },
    {
      "nct_id": "NCT00125840",
      "title": "Clofarabine in Adult Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Leukemia, Lymphocytic, Acute, Pediatric",
        "Leukemia, Lymphocytic, Acute, Adult",
        "Leukemia, Myelocytic, Acute, Pediatric",
        "Leukemia, Myelocytic, Acute, Adult",
        "Myelodysplastic Syndromes, Adult"
      ],
      "interventions": [
        {
          "name": "clofarabine (IV formulation)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-08",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2014-02-05",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Tyler, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125840"
    },
    {
      "nct_id": "NCT05473910",
      "title": "A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML",
        "MDS"
      ],
      "interventions": [
        {
          "name": "SOC + TSC-101",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "OTHER"
        },
        {
          "name": "SOC + TSC-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2022-11-01",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 21,
      "location_summary": "Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05473910"
    },
    {
      "nct_id": "NCT06411626",
      "title": "Home Reported Outcomes in PNH",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [
        {
          "name": "PNH-relevant therapies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 128,
      "start_date": "2024-06-11",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-10-26T19:26:50.872Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06411626"
    }
  ]
}